Atara Biotherapeutics (NASDAQ:ATRA) Posts Quarterly Earnings Results, Beats Expectations By $0.84 EPS

Atara Biotherapeutics (NASDAQ:ATRA) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($2.93) earnings per share for the quarter, beating the consensus estimate of ($3.77) by $0.84, Zacks reports. The business had revenue of $40.19 million for the quarter, compared to the consensus estimate of $23.00 million. During the same period in the previous year, the business posted ($16.50) EPS.

Atara Biotherapeutics Stock Performance

NASDAQ:ATRA traded up $2.31 on Wednesday, hitting $13.98. 223,536 shares of the stock were exchanged, compared to its average volume of 106,492. Atara Biotherapeutics has a 52 week low of $6.48 and a 52 week high of $39.50. The company’s 50-day moving average price is $8.79 and its 200 day moving average price is $10.27.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ATRA. The Goldman Sachs Group decreased their price target on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a report on Wednesday, July 17th. Canaccord Genuity Group upped their price objective on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Finally, Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their target price for the company from $25.00 to $18.00 in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $16.67.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.